NCT07837830 Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)
| NCT ID | NCT07837830 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Valley Health System |
| Condition | Pulmonary Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2026-09 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 32 participants in total. It began in 2026-09 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective open-label matched-control pilot study evaluates whether inhaled treprostinil improves exercise pulmonary vascular resistance and functional outcomes in adults with interstitial lung disease or connective tissue disease and exercise-induced pulmonary hypertension. Participants will receive inhaled treprostinil plus standard care or standard care alone and will be followed for 6 months, with an optional extension to 12 months.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * ILD diagnosis or CTD diagnosis * WHO Functional Class II-III * Resting RHC: * mPAP ≤20 mmHg * PVR ≤2 WU * PAWP ≤15 mmHg * Exercise-induced pulmonary hypertension on iCPET * Able to provide informed consent Exclusion Criteria: * Resting pulmonary hypertension * Significant left heart disease * CTEPH * Acute PE within 6 months * Current PAH-targeted therapy * Pregnancy or breastfeeding * Severe renal or hepatic impairment * Inability to perform exercise testing * Contraindication to RHC * Treprostinil hypersensitivity
Contact & Investigator
Ashish Rai Rai, MD
PRINCIPAL INVESTIGATOR
Valley Health System
Frequently Asked Questions
Who can join the NCT07837830 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07837830 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07837830 currently recruiting?
Yes, NCT07837830 is actively recruiting participants. Contact the research team at Raias@valleyhealth.com for enrollment information.
Where is the NCT07837830 trial being conducted?
This trial is being conducted at Paramus, United States, Paramus, United States.
Who is sponsoring the NCT07837830 clinical trial?
NCT07837830 is sponsored by Valley Health System. The principal investigator is Ashish Rai Rai, MD at Valley Health System. The trial plans to enroll 32 participants.